{"commentary":{"count":138,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":94,"youtube":19,"podcast":19,"x_video":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05239728\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05239728","nct_id":"NCT05239728","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05239728. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants receive belzutifan 120 mg orally once daily (QD) for up to approximately 54 weeks PLUS pembrolizumab 400 mg via intravenous (IV) infusion once every 6 weeks (Q6W) for up to 9 administrations (up to approximately 54 weeks).","label":"Belzutifan + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive placebo orally QD for up to approximately 54 weeks PLUS pembrolizumab 400 mg via IV infusion once Q6W for up to 9 administrations (up to approximately 54 weeks).","label":"Placebo + Pembrolizumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-09-28","type":"ESTIMATED"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":1800,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Belzutifan","type":"DRUG"},{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-05-15","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-10-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-Free Survival (DFS)","timeFrame":"Up to approximately 54 months"}],"references":[{"citation":"Choueiri TK, Motzer RJ, Karam JA, Yip W, Suarez C, Ye D, He Z, Caglevic C, Ferguson T, Chang YH, Rojas C, Iacovelli R, Urun Y, Verzoni E, Vazquez Limon JC, Porta C, Uzzo RG, Lee JL, Venugopal B, McKay RR, Hammers H, Miyake H, Chahoud J, Liu H, Burgents JE, Sharma M, Powles TB; LITESPARK-022 Investigators. Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma. N Engl J Med. 2026 Jul 2;395(1):32-43. doi: 10.1056/NEJMoa2518245.","pmid":"42384869","type":"DERIVED"}],"start_date":{"date":"2022-03-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)","url":"https://clinicaltrials.gov/study/NCT05239728"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05239728"}